News

2021

• Intranasal vaccines aim to stop COVID-19 where it starts C&EN
• Codagenix and Univercells Announce Research Collaboration on Undisclosed, High-Priority Human Vaccine Target with Global Public Health Demand PR Newswire
• Codagenix Appoints Johanna Kaufmann, Ph.D., Executive Vice President, Oncology to Lead Customization of Oncolytic Viruses for Solid Tumors PR Newswire
• Codagenix Appoints Linda Maldonado as VP, Biologics Chemistry and Manufacturing Controls PR Newswire
• Developers seek to bypass needle for inoculation China Daily
• Codagenix Expands Senior Management Team With Three New Appointments PR Newswire
• Codagenix Secures U.S. Patent for Codon-Deoptimized RSV Vaccine Candidates PR Newswire
• Inhaling away the virus: Is the next generation of COVID vaccines on their way? ABC News
• Codagenix and Serum Institute of India Initiate Dosing in Phase 1 Trial of COVI-VAC, a Single Dose, Intranasal, Live Attenuated Vaccine for COVID-19 PR Newswire

2020

• Codagenix CEO speaking at “The Quest for a COVID-19 Vaccine” event
• Codagenix and Serum Institute of India Announce Commencement of First-in-Human Trial of COVI-VAC, A Single Dose, Intranasal Live Attenuated Vaccine for COVID-19 PR Newswire
• Codagenix is a finalist in the Buzz of BIO competition!
• Codagenix Inc. Completes Dosing for Phase 1 Trial of Live-Attenuated, Intranasal Vaccine for Respiratory Syncytial Virus (RSV) PR Newswire
• Codagenix, Inc. Appoints Jeffrey Fu, Ph.D., Chief Business Officer PR Newswire
• Serum Institute of India Initiates Manufacturing of Codagenix’s Intranasal Live-Attenuated COVID-19 Vaccine Candidate PR Newswire
• Synthetic biologists have created a slow-growing version of the coronavirus to give as a vaccine MIT Technology Review
• What if the First Coronavirus Vaccines Aren’t the Best? New York Times
• Biotech Startup Codagenix Plans Human Trials for COVID-19 Vaccine BioSpace
• NIH Supports Codagenix’s Human Codon Deoptimized RSV Vaccine Via $2.2M Grant and a Renewed R&D Contract for Scale-up Manufacturing
• Codagenix Announces the Synthesis and Preliminary Safety of Scalable, Live-attenuated Vaccine Candidate Against COVID-19 PR Newswire
• Codagenix and Serum Institute of India Initiate Co-Development of a Scalable, Live-Attenuated Vaccine Against the 2019 Novel Coronavirus, COVID-19 PR Newswire
• Gates vets at Adjuvant back Codagenix’s software-driven approach to recoding RSV, flu, oncolytic viruses and more Endpoints News
• Codagenix Raises $20 Million in Series B Funding for Continued Development of RSV, Influenza and Oncolytic Virus Products PR Newswire

2019

• Codagenix and USDA-ARS Renew CRADA for Continued Development of Synthetic, Multivalent Foot-and-Mouth Disease Virus (FMDV) Vaccine
• Codagenix presenting at ID Week
• Codagenix Inc. Strengthens Leadership Team with Experienced Chief Medical Officer
• Codagenix Inc. Announces Award of $1M US Army Contract for Continued Development of Contemporary, Balanced Dengue Vaccine
• Codagenix: Combating Deadly Diseases with a Fast Track to Vaccine Development Wired

2017

• RSV vaccine player Codagenix snags $3M in public and private investment FiercePharma
• Demonstration of Multi-Season Efficacy and Immunogenicity of CodaVax Intranasal Influenza Vaccine

2015

• LI biotech Codagenix receives $2M equity investment Newsday
• Codagenix Gets $100K USDA Grant For Foot And Mouth Vaccine Innovateli
• Codagenix snags grant to develop vaccine for foot-and-mouth disease Newsday